Humacyte, Inc.

Humacyte, Inc., listed under the ticker AHAC, is a Morrisville, North Carolina-based regenerative medicine company that entered the public markets through a business combination with Alpha Healthcare Acquisition Corp., a healthcare-focused special purpose acquisition company that completed its IPO in 2020 and was sponsored by Alpha Healthcare Advisors. The de-SPAC merger closed in August 2021, bringing Humacyte's human acellular vessel platform — bioengineered implants designed for vascular reconstruction — under the public-company reporting umbrella. The company filed an 8-K with the Securities and Exchange Commission on June 9, 2026, as part of its ongoing disclosure obligations. For full filing history, deal timelines, and SPAC transaction analytics on Humacyte and hundreds of other post-merger companies, sign up for complete data access at SpacDesk.